可注射富血小板纤维蛋白治疗轻中度女性型脱发的疗效与安全性

李曼 ,  白悦 ,  叶珍珍 ,  张迪 ,  贺子萱 ,  葛紫薇 ,  谭安生 ,  韩羽 ,  陈安欣 ,  王文慧 ,  禚风麟

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (7) : 853 -858.

PDF (1647KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (7) : 853 -858. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.07.006
论著

可注射富血小板纤维蛋白治疗轻中度女性型脱发的疗效与安全性

作者信息 +

Efficacy and safety of injectable platelet-rich fibrin in the treatment of mild to moderate female pattern hair loss

Author information +
文章历史 +
PDF (1685K)

摘要

目的 评估可注射富血小板纤维蛋白(injectable platelet-rich fibrin,i-PRF)治疗轻中度女性型脱发(female pattern hair loss,FPHL)的临床疗效与安全性,并探索性分析 i-PRF 疗效影响因素。方法 本研究来源于一项前瞻性、随机对照研究的二次分析。 纳入 2024 年 3 月至 2025 年 4 月于首都医科大学附属北京友谊医院及北京大学第三医院门诊就诊的 29 例 Sinclair Ⅱ~ Ⅲ级 FPHL 患者,接受 i-PRF 治疗,每 4 周 1 次,共 4 次,随访至 24 周。 分别于基线、治疗 12 周及 24 周拍摄临床大体图像,并采用毛发镜检测目标区域非毳毛数(non-vellus target area hair count,TAHC)及毛干直径(hair diameter,HD),并记录所有不良事件。 采用 Mann-Whitney U 检验分析分类影响因素的组间疗效差异,Spearman 秩相关分析连续影响因素与疗效的相关性,采用多元线性回归分析(Enter 法)进行疗效影响因素分析。结果 共 27 例患者完成研究。 治疗 12 周时,TAHC 由 112(105, 120)根/ cm2升至 128(110, 150)根/ cm2,较基线增加 12(5, 28)根/ cm2,增长率为 10. 5(4. 2, 24. 5)%,差异有统计学意义(P = 0. 045);毛干直径由 42. 5(39. 8, 45. 2)μm 升至 52. 0(47. 0, 58. 0)μm,增加 7. 5(3. 0, 12. 5)μm,增长率 18. 0(7. 5, 29. 0)%,差异有统计学意义(P<0. 001)。 至治疗 24 周,TAHC 进一步提高至 141(125, 158)根/ cm2,差异有统计学意义(P<0. 001),增长率 24. 8(18. 5, 32. 0)%;毛干直径持续改善至 55. 0(50. 0, 61. 0) μm,差异有统计学意义(P = 0. 008),增长率 21. 5(16. 0, 27. 0)%。 总不良事件发生率为 10. 34%(3/ 29 例),以轻微头皮瘙痒、一过性头痛为主,无严重不良事件。 多元线性回归分析显示,基线 TAHC 是 i-PRF 疗效的独立影响因素(P<0. 05),年龄、BMI、脱发病程、Sinclair 分级、脱发家族史及基线 HD 对疗效无显著独立影响。结论 本研究初步验证 i-PRF 可提升 FPHL 患者毛发密度与直径,安全性良好。 基线 TAHC 较低的 FPHL 患者可能获得更大的临床改善。

Abstract

Objective To evaluate the clinical efficacy and safety of injectable platelet-rich fibrin (i-PRF) in the treatment of mild to moderate female pattern hair loss (FPHL), and to analyze the related clinical factors affecting the therapeutic efficacy of i-PRF. Methods This was a secondary analysis of a prospective, randomized controlled trial. A total of 29 FPHL patients with Sinclair grade Ⅱ-Ⅲ, who attended the outpatient clinics of Beijing Friendship Hospital, Capital Medical University and Peking University Third Hospital from March 2024 to April 2025, were enrolled. All patients received i-PRF treatment once every 4 weeks for a total of 4 sessions, with follow-up up to 24 weeks. Standardized clinical photographs were taken at baseline, week 12 and week 24. Trichoscopic examination was performed to measure the non-vellus target area hair count (TAHC) and hair diameter (HD) in the target area, and all adverse events were recorded. The Mann-Whitney U test was used to compare the intergroup differences in efficacy for categorical influencing factors; Spearman rank correlation analysis was employed to assess the correlation between continuous influencing factors and efficacy; and multiple linear regression (enter method) was performed to identify independent influencing factors of efficacy. Results A total of 27 patients completed the trial. At week 12, TAHC significantly increased from 112 (105, 120) hairs/ cm2at baseline to 128 (110, 150) hairs/ cm2, with a median increase of 12 (5, 28) hairs/ cm2and a median growth rate of 10. 5 (4. 2, 24. 5)% (P= 0. 045); hair diameter significantly increased from 42. 5 (39. 8, 45. 2) μm to 52. 0 (47. 0, 58. 0) μm, with a median increase of 7. 5 (3. 0, 12. 5) μm and a median growth rate of 18. 0 (7. 5, 29. 0)% (P<0. 001). At week 24, TAHC further significantly increased to 141 (125, 158) hairs/ cm2(P<0. 001), with a median growth rate of 24. 8 (18. 5, 32. 0) %; hair diameter continued to improve to 55. 0 (50. 0, 61. 0) μm (P= 0. 008), with a median growth rate of 21. 5 (16. 0, 27. 0) %. The overall incidence of adverse events was 10. 34% (3/ 29), mainly presenting as mild scalp pruritus and transient headache, without severe adverse effects. Multiple linear regression analysis revealed that baseline TAHC was an independent influencing factor for i-PRF efficacy (P<0. 05), while age, BMI, disease duration, Sinclair grade, family history of AGA, and baseline HD showed no significant independent effect on efficacy in this model(P>0. 05). Conclusion This preliminary study indicates that i-PRF can improve hair density and hair shaft diameter in patients with FPHL with a favorable safety profile. Patients with FPHL and lower baseline TAHC may achieve greater clinical improvement.

关键词

女性型脱发 / 可注射富血小板纤维蛋白 / 临床疗效 / 安全性 / 疗效影响因素

Key words

female pattern hair loss / injectable platelet-rich fibrin / clinical efficacy / safety / influencing factors of efficacy

引用本文

引用格式 ▾
李曼,白悦,叶珍珍,张迪,贺子萱,葛紫薇,谭安生,韩羽,陈安欣,王文慧,禚风麟. 可注射富血小板纤维蛋白治疗轻中度女性型脱发的疗效与安全性[J]. 中国输血杂志, 2026, 39(7): 853-858 DOI:10.13303/j.cjbt.issn.1004-549x.2026.07.006

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

KEARNEY C A, BRINKS A L, LAWRENCE C N, et al. Androgenetic alopecia in women:a narrative review of pathophysiology, clinical evaluation, and treatments[J].Am J Clin Dermatol, 2026, 27(2):363-389.

[2]

CHOUKROUN J, GHANAATI S. Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrates advances patients′ own inflammatory cells, platelets and growth factors:the first introduction to the low speed centrifugation concept[J].Eur J Trauma Emerg Surg, 2017, 44(1):87-95.

[3]

SCHIAVONE G, PARADISI A, RICCI F, et al. Injectable platelet-, leukocyte-, and fibrin-rich plasma (iL-PRF) in the management of androgenetic alopecia[J].Dermatol Surg, 2018, 44(9):1183-1190.

[4]

SHARMA S, VHADRA B, QUINLAN D J, et al. Injectable platelet-rich fibrin for treatment of female pattern hair loss[J].J Cosmet Laser Ther, 2024, 26(1):17-25.

[5]

YAO S L, CHEN X Y, LI S, et al. New tool in our arsenal:efficacy of injectable platelet-rich fibrin (i-PRF) in androgenetic alopecia treatment[J].Arch Dermatol Res, 2025, 317(1):493.

[6]

周城, 范卫新, 方红, 等. 中国雄激素性秃发诊疗指南(2023)[J].临床皮肤科杂志, 2024, 53(12):752-758.

[7]

ZHOU C, FAN W X, FANG H, et al. Chinese guideline for diagnosis and treatment of androgenetic alopecia (2023)[J].J Clin Dermatol, 2024, 53(12):752-758.

[8]

MAJD A, SANTOS L D N, CHU T W, et al. Hair distribution width -a novel trichoscopy parameter for hair miniaturization in androgenetic alopecia[J].J Eur Acad Dermatol Venereol, 2019, 33(10):e371-e372.

[9]

KAMISHIMA T, HIRABE C, MYINT K Z Y, et al. Divergent progression pathways in male androgenetic alopecia and female pattern hair loss: Trichoscopic perspectives[J].J Cosmet Dermatol, 2024, 23 (5): 1828-1839.

[10]

李育蓉, 谢雨彤, 于惠泽, 等. 可注射 i-PRF 与 CGF 治疗男性雄激素性秃发的自身半头对照研究[J].皮肤科学通报, 2025, 42(5):520-527.

[11]

LI Y R, XIE Y T, YU H Z, et al. Split-scalp controlled study on i-PRF and CGF in the treatment of male androgenetic alopecia[J].Dermatol Bull, 2025, 42(5):520-527.

[12]

卢孔烨. 可注射富血小板纤维蛋白调节人毛乳头细胞增殖、迁移、诱导能力促进毛发再生[D].大连医科大学, 2022.

[13]

LU K Y. Injectable platelet rich fibrin facilitates hair regeneration by promoting human dermal papilla cell proliferation, migration, and trichogenic inductivity[D]. Dalian Medical University, 2022.

[14]

刘广亚, 许育兵, 朱展鸿, 等. 自体富血小板血浆治疗雄激素源性脱发临床疗效的影响因素分析[J].中国输血杂志, 2022, 35(12):1243-1247.

[15]

LIU G Y, XU Y B, ZHU Z H, et al. Influencing factors of clinical efficacy of autologous platelet-rich plasma in the treatment of androgenetic alopecia[J].Chin J Blood Transfusion, 2022, 35(12):1243-1247.

[16]

MIRON R J, ZHANG Y F. Autologous liquid platelet rich fibrin:a novel drug delivery system[J].Acta Biomater, 2018, 75(1):35-51.

[17]

MIRON R J, GRUBER R, FARSHIDFAR N, et al. Ten years of injectable platelet-rich fibrin[J].Periodontol, 2000, 2024, 94(1):92-113.

AI Summary AI Mindmap
PDF (1647KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉